EQS-News: Dermapharm Holding SE erfüllt alle Erwartungen trotz multipler gesamtwirtschaftlicher Herausforderungen
Retrieved on:
Wednesday, April 10, 2024
Grünwald, 28 March 2024 – Dermapharm Holding SE ("Dermapharm"), a rapidly growing manufacturer of branded pharmaceuticals, today published its full Annual Report 2023.
Dermapharm Holding SE hits upper end of guidance range for adjusted EBITDA, primarily due to steadily growing international presence in branded business
Consolidated revenue and EBITDA (adjusted) stay on course, climbing to EUR 866.6 million and EUR 243.8 million, respectively
Dermapharm Holding SE publishes H1 2023 financial report, confirms outlook for 2023 overall
Dermapharm successfully maintains its growth trend as planned in the first six months of financial year 2023.